Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus rating of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $326.25.

Several research analysts have recently weighed in on KRYS shares. Jefferies Financial Group upped their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Chardan Capital upped their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. HC Wainwright reissued a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Finally, Bank of America lifted their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, Director Dino A. Rossi sold 18,950 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the sale, the director owned 78,691 shares in the company, valued at $20,570,614.31. This represents a 19.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 116,611 shares of company stock worth $30,008,839. Company insiders own 13.70% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in KRYS. EFG Asset Management North America Corp. raised its position in shares of Krystal Biotech by 18.4% during the 3rd quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after purchasing an additional 4,217 shares during the period. Edgestream Partners L.P. acquired a new stake in Krystal Biotech in the second quarter worth $2,705,000. Voya Investment Management LLC lifted its stake in Krystal Biotech by 46.7% in the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after buying an additional 29,915 shares during the last quarter. Atle Fund Management AB boosted its holdings in shares of Krystal Biotech by 109.3% during the third quarter. Atle Fund Management AB now owns 42,191 shares of the company’s stock valued at $7,448,000 after acquiring an additional 22,033 shares during the period. Finally, Norges Bank bought a new stake in Krystal Biotech in the 2nd quarter valued at about $38,861,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $275.64 on Monday. The business has a 50-day moving average of $268.99 and a two-hundred day moving average of $215.34. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $298.30. The firm has a market capitalization of $8.06 billion, a PE ratio of 40.24 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. As a group, research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.